AUT06NG

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NameAUT06NG

Drug Alias NameAUT06NG

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyCell and gene therapy > Gene therapy

Mechanisms of ActionAnti-GD2

TargetsDisialoganglioside GD2

Therapy Area/IndicationsSmall Cell Lung CarcinomaSkin NeoplasmsNeuroblastoma +[4]

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesUniversity College London

China Registration ClassN/A

Develop Information

Active CompaniesAutolus University College London

Inactive CompaniesN/A

Active IndicationsSmall Cell Lung CarcinomaSkin NeoplasmsNeuroblastoma +[4]

Inactive IndicationsN/A

Other Information

ATC CodeN/A